PHAS

PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS

Overview Fund Activity
Delisted

PHAS was delisted on the 2nd of November, 2022.

Back to rankings

52 hedge funds and large institutions have $245M invested in PhaseBio Pharmaceuticals, Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 36 funds opening new positions, 15 increasing their positions, 1 reducing their positions, and 3 closing their positions.

Holders
52
Holders Change
+33
Holders Change %
+173.68%
% of All Funds
1.13%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
%
% of All Funds
0.02%
New
36
Increased
15
Reduced
1
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
NMC
1
NEA Management Company
Maryland
$87.2M
2
DM
2
Deerfield Management
New York
$11.2M
3
BlackRock
3
BlackRock
New York
$11.7M
4
FCM
4
Farallon Capital Management
California
$9.93M
5
Vanguard Group
5
Vanguard Group
Pennsylvania
$8.84M

Top Sellers

1
Millennium Management
1
Millennium Management
New York
$0
2
Susquehanna International Group
2
Susquehanna International Group
Pennsylvania
$0
3
TEE
3
Tibra Equities Europe
United Kingdom
$0
4
Bank of America
4
Bank of America
North Carolina
$35K
Name Holding Trade Value Shares
Change 		Shares
Change %
GT
51
Glenmede Trust
Pennsylvania
$65 +$65 +5,000 New
Millennium Management
52
Millennium Management
New York
– -$1.16M -121,979 Closed
Susquehanna International Group
53
Susquehanna International Group
Pennsylvania
– -$407K -42,845 Closed
TEE
54
Tibra Equities Europe
United Kingdom
– -$217K -22,778 Closed
1 2
3